Cover Image
市場調查報告書

腎絲球腎炎:開發中產品分析

Glomerulonephritis - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 192609
出版日期 內容資訊 英文 157 Pages
訂單完成後即時交付
價格
Back to Top
腎絲球腎炎:開發中產品分析 Glomerulonephritis - Pipeline Review, H2 2017
出版日期: 2017年09月19日 內容資訊: 英文 157 Pages
簡介

腎絲球腎炎 (GN,腎小球疾病) 是腎臟疾病之一,特徵是腎臟的腎小球引起發炎。在腎絲球腎炎的要素中,有喉嚨感染鏈球菌 (鏈球菌性咽頭炎) ,及免疫疾病 (狼瘡等) 、第一型、第二型糖尿病,各種病毒 (HIV,B型肝炎,C型肝炎等) 等。使感染概率上升的要素,有家族的感染經歷,重要的病因存在,高血壓等。一般的症狀有尿中帶血 (尿為黑色/紅鏽色/紅色) ,及泡沫狀,在臉、眼、腳後跟、腳、、腹部的腫脹 (水腫)的發生等。治療方法根據疾病要素而不相同,使用藥物療法和生活習慣改善,透析,腎臟移植等。

本報告提供全球各國的腎絲球腎炎治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

簡介

  • 調查範圍

腎絲球腎炎概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品:各企業
  • 開發中產品:各大學/機關
  • 企業開發中的產品
  • 大學/機關研究中的產品

腎絲球腎炎:治療藥的評估

  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發腎絲球腎炎的治療藥的企業

  • Achillion Pharmaceuticals Inc
  • Anthera Pharmaceuticals Inc
  • Biogen Inc
  • Bristol-Myers Squibb Company
  • Cellmid Ltd
  • ChemoCentryx Inc
  • Complexa Inc
  • Dimerix Bioscience Pty Ltd
  • GlaxoSmithKline Plc
  • Merck KGaA
  • Omeros Corp
  • Pfizer Inc
  • Pharmalink AB
  • Ra Pharmaceuticals Inc
  • Retrophin Inc
  • Rigel Pharmaceuticals Inc
  • Shire Plc
  • Visterra Inc

藥物簡介

腎絲球腎炎:暫停中的計劃

腎絲球腎炎:開發中止的產品

腎絲球腎炎:產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9725IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glomerulonephritis - Pipeline Review, H2 2017, provides an overview of the Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline landscape.

Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat known as strep throat, immune diseases, such as lupus, Type 1 diabetes and type 2 diabetes and viruses, such as HIV, hepatitis B virus, and hepatitis C virus. Factors that increase chances of getting glomerulonephritis include family history of glomerulonephritis, the presence of a known cause of glomerulonephritis and high blood pressure. Common symptoms of glomerulonephritis are blood in the urine (dark, rust-colored, or brown urine), foamy urine, swelling (edema) of the face, eyes, ankles, feet, legs, or abdomen. Treatment will depend on the cause of glomerulonephritis such as medications, lifestyle changes, dialysis and transplant.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glomerulonephritis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 11, 5, 13 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Glomerulonephritis (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Glomerulonephritis - Overview
    • Glomerulonephritis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Glomerulonephritis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Glomerulonephritis - Companies Involved in Therapeutics Development
    • Achillion Pharmaceuticals Inc
    • Anthera Pharmaceuticals Inc
    • Biogen Inc
    • Bristol-Myers Squibb Company
    • Cellmid Ltd
    • ChemoCentryx Inc
    • Complexa Inc
    • Dimerix Bioscience Pty Ltd
    • GlaxoSmithKline Plc
    • Merck KGaA
    • Omeros Corp
    • Pfizer Inc
    • Pharmalink AB
    • Ra Pharmaceuticals Inc
    • Retrophin Inc
    • Rigel Pharmaceuticals Inc
    • Shire Plc
    • Visterra Inc
  • Glomerulonephritis - Drug Profiles
    • (irbesartan + propagermanium) - Drug Profile
    • abatacept - Drug Profile
    • ACH-4471 - Drug Profile
    • ACH-5228 - Drug Profile
    • AMY-101 - Drug Profile
    • atacicept - Drug Profile
    • avacopan - Drug Profile
    • AVX-002 - Drug Profile
    • BaxB-01 - Drug Profile
    • BaxG-03 - Drug Profile
    • belimumab - Drug Profile
    • blisibimod - Drug Profile
    • budesonide - Drug Profile
    • CAB-102 - Drug Profile
    • CCX-140 - Drug Profile
    • CXA-10 - Drug Profile
    • ERG-240 - Drug Profile
    • fostamatinib disodium - Drug Profile
    • losmapimod - Drug Profile
    • Monoclonal Antibodies to Inhibit ITGAM for Cardiovascular, Immunology and Kidney Diseases - Drug Profile
    • OMS-721 - Drug Profile
    • PBF-677 - Drug Profile
    • PF-06730512 - Drug Profile
    • PF-1355 - Drug Profile
    • Recombinant Enzyme for Immunoglobulin A Nephropathy - Drug Profile
    • rituximab - Drug Profile
    • SHP-627 - Drug Profile
    • Small Molecule to Inhibit Factor D for C3 glomerulopathy and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile
    • sparsentan - Drug Profile
    • Synthetic Peptides to Inhibit Factor D for Age-Related Macular Degeneration, Paroxysmal Nocturnal Hemoglobinuria and Renal Disease - Drug Profile
    • TM-5484 - Drug Profile
    • Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile
    • VAR-200 - Drug Profile
    • VIS-649 - Drug Profile
  • Glomerulonephritis - Dormant Projects
  • Glomerulonephritis - Discontinued Products
  • Glomerulonephritis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Glomerulonephritis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Glomerulonephritis - Pipeline by Achillion Pharmaceuticals Inc, H2 2017
  • Glomerulonephritis - Pipeline by Anthera Pharmaceuticals Inc, H2 2017
  • Glomerulonephritis - Pipeline by Biogen Inc, H2 2017
  • Glomerulonephritis - Pipeline by Bristol-Myers Squibb Company, H2 2017
  • Glomerulonephritis - Pipeline by Cellmid Ltd, H2 2017
  • Glomerulonephritis - Pipeline by ChemoCentryx Inc, H2 2017
  • Glomerulonephritis - Pipeline by Complexa Inc, H2 2017
  • Glomerulonephritis - Pipeline by Dimerix Bioscience Pty Ltd, H2 2017
  • Glomerulonephritis - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Glomerulonephritis - Pipeline by Merck KGaA, H2 2017
  • Glomerulonephritis - Pipeline by Omeros Corp, H2 2017
  • Glomerulonephritis - Pipeline by Pfizer Inc, H2 2017
  • Glomerulonephritis - Pipeline by Pharmalink AB, H2 2017
  • Glomerulonephritis - Pipeline by Ra Pharmaceuticals Inc, H2 2017
  • Glomerulonephritis - Pipeline by Retrophin Inc, H2 2017
  • Glomerulonephritis - Pipeline by Rigel Pharmaceuticals Inc, H2 2017
  • Glomerulonephritis - Pipeline by Shire Plc, H2 2017
  • Glomerulonephritis - Pipeline by Visterra Inc, H2 2017
  • Glomerulonephritis - Dormant Projects, H2 2017
  • Glomerulonephritis - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Glomerulonephritis - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Glomerulonephritis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top